Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | ELANE | P08246 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17280822 | 1.00 | ALDH1A1 (0.64) | ALDH1A1KMT2AMAPK1CA12CA9 | |
| SCHEMBL6699242 | 1.00 | ALDH1A1 (0.64) | ALDH1A1KMT2AMAPK1CA12CA9 | |
| SCHEMBL12869027 | 0.85 | ALDH1A1 (0.56) | ALDH1A1KMT2AMAPK1CA12CA9 | |
| SCHEMBL4257901 | 0.84 | CYP1B1 (0.62) | ALDH1A1KMT2AMAPT | |
| SCHEMBL9340887 | 0.83 | ALDH1A1 (0.53) | ALDH1A1KMT2AMAPK1CA12CA9 | |
| SCHEMBL30377710 | 0.83 | ALDH1A1 (0.53) | ALDH1A1KMT2ACA12CA9RAB9A | |
| SCHEMBL5328150 | 0.83 | ALDH1A1 (0.62) | ALDH1A1KMT2AMAPK1CA12CA9 | |
| SCHEMBL8939993 | 0.83 | ALDH1A1 (0.64) | ALDH1A1KMT2AMAPK1CA12CA9 | |
| SCHEMBL4482770 | 0.83 | ALDH1A1 (0.53) | ALDH1A1KMT2ACA12CA9RAB9A | |
| SCHEMBL28989527 | 0.82 | ALDH1A1 (0.59) | ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040087802-A1 | Process for preparing glycidylphthalimide | OSAKA SODA CO., LTD. (JP) | 2004-05-06 | — | — | US | claimed |
| CN-115677511-B | Synthesis method of 2, 2-difluoropropylamine hydrochloride | 南通华祥医药科技有限公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-115677511-A | Synthetic method of2, 2-difluoropropylamine hydrochloride | 南通华祥医药科技有限公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-107540647-B | -amino alkyl furan phenol ether and preparation method and application thereof | 湖南大学 | 2020-11-24 | — | — | CN | disclosed |
| US-9873692-B2 | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873692-B2 | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-01-23 | — | — | US | disclosed |
| CN-107540647-A | δ aminoalkyl furans phenolic ethers and preparation method and application | 湖南大学 | 2018-01-05 | — | — | CN | disclosed |
| US-20170334901-A1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-11-23 | — | — | US | disclosed |
| US-20170334901-A1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-11-23 | — | — | US | disclosed |
| US-9771316-B2 | Phenoxyalkylamine compound | OSAKA UNIVERSITY (JP) | 2017-09-26 | — | — | US | disclosed |
| US-20070270457-A1 | Quinolinone-carboxamide compounds as 5-HT, receptor agonists | ALFASIGMA S.P.A. (IT) | 2007-11-22 | — | — | US | disclosed |
| US-20070270457-A1 | Quinolinone-carboxamide compounds as 5-HT, receptor agonists | ALFASIGMA S.P.A. (IT) | 2007-11-22 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| WO-2005100350-A1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
| EP-0790826-A4 | DIHYDROPYRIMIDINES AND USES THEREOF | SYNAPTIC PHARMA CORP (US) | 1998-11-11 | — | — | EP | disclosed |
| CN-1173132-A | Dihydropyrimidine compounds and application thereof | SYNAPTIC PHARMACEUTIC CORP (US) | 1998-02-11 | — | — | CN | disclosed |
| EP-0790826-A1 | DIHYDROPYRIMIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1997-08-27 | — | — | EP | disclosed |
| EP-0629617-A1 | Heteroatom-bearing ligands and metal complexes thereof | BRACCO International B.V. (NL) | 1994-12-21 | — | — | EP | disclosed |
| EP-0165110-A1 | Optically active isocarbostyril derivatives and a method of preparing the same | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1985-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | ALDH1A1 2353/4885KMT2A 2236/4885MAPK1 3848/4885 |
| US-20070270457-A1 | Quinolinone-carboxamide compounds as 5-HT, receptor agonists | HTR4, HTR5A, HTR1A | ALDH1A1 2360/4885KMT2A 1436/4885MAPK1 2918/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | ALDH1A1 2353/4885KMT2A 2236/4885MAPK1 3848/4885 |
| US-20170334901-A1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR5A, HTR1A | ALDH1A1 2540/4885KMT2A 1511/4885MAPK1 2970/4885 |
| US-20040087802-A1 | Process for preparing glycidylphthalimide | EZH1, ALKBH3, PHF2 | ALDH1A1 1435/4885KMT2A 251/4885MAPK1 1899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.